Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    McDonald’s to open 10,000 stores by 2027, embracing AI technology

    December 7, 2023

    UAE hosts Russian president in landmark state visit

    December 7, 2023

    Start your day right with complex carbs to enhance weight loss and blood sugar control

    December 5, 2023
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Arab NarrativeArab Narrative
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • Lifestyle
    • News
    • Sports
    • Technology
    • Travel
    Arab NarrativeArab Narrative
    Home » Early results of a study on an Alzheimer’s drug show promise
    Health

    Early results of a study on an Alzheimer’s drug show promise

    September 30, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    The shares of Biogen and other drugmakers researching Alzheimer’s disease surged Wednesday after Japan’s Eisai Co. Ltd.. reported its potential treatment appeared to slow the disease in a late-stage study. Lecanemab, the drugmaker’s treatment, reduced patients’ clinical decline by 27% after 18 months of infused treatment compared to placebos or fake drugs, according to AP reports.

    Early results of a study on an Alzheimer's drug show promiseThe results of Eisai’s global study of nearly 1,800 people with early-stage Alzheimer’s were announced late Tuesday. Mental decline and ability to do daily activities such as dressing and eating were measured using a scale. Eisai Co. Ltd. said it would present full research results at a conference in late November. The findings will also be published in a peer-reviewed medical journal.

    The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Biogen and Eisai will jointly promote the drug. Researchers usually caution against evaluating a study before full results are released. According to Mizuho Securities analyst Graig Suvannavejh, the initial findings are “quite robust” and support regulatory approval.

    According to the Alzheimer’s Association, the findings provide the highest hope so far for treating the disease’s underlying causes. Alzheimer’s disease affects some 6 million Americans and many more worldwide, gradually destroying parts of the brain that control memory, reasoning, communication, and basic daily functions.

    There is no known cure for Alzheimer’s disease. Researchers are still trying to understand what causes the disease, and long-standing treatments only manage symptoms. It has been nearly two decades since Biogen introduced a new Alzheimer’s drug. However, it has generally flopped after debuting at $56,000 annually, which Biogen later reduced. Due to weak evidence that the drug slows Alzheimer’s progression, doctors have been hesitant to prescribe it. Due to the drug’s high price and uncertain benefits, insurers have blocked or restricted coverage.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Start your day right with complex carbs to enhance weight loss and blood sugar control

    December 5, 2023

    Revolutionizing diabetes care with saliva tests replacing finger pricks

    December 2, 2023

    New insights into natural remedies for heart health

    November 30, 2023
    Latest News

    McDonald’s to open 10,000 stores by 2027, embracing AI technology

    December 7, 2023

    UAE hosts Russian president in landmark state visit

    December 7, 2023

    Start your day right with complex carbs to enhance weight loss and blood sugar control

    December 5, 2023

    Innovative construction solutions unveiled at Dubai’s Big 5 Global

    December 5, 2023

    UAE and Morocco forge new path with innovative partnership declaration

    December 5, 2023

    $9 billion boost from Global Fund for climate-impacted health systems

    December 5, 2023

    Shaping tomorrow’s technology today with the top 11 companies leading the AI revolution

    December 3, 2023

    New York, L.A., and San Francisco among the world’s most expensive

    December 3, 2023
    © 2021 Arab Narrative | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.